NCT03179501View on ClinicalTrials.gov

NP001, Alzheimer's Disease, and Blood Markers of Inflammation

PHASE1TerminatedINTERVENTIONAL
Enrollment

4

Participants

Timeline

Start Date

September 1, 2017

Primary Completion Date

July 31, 2018

Study Completion Date

July 31, 2018

Conditions
Alzheimer Disease
Interventions
DRUG

NP001

NP001

DRUG

Placebo

Normal saline

Trial Locations (1)

96813

University of Hawaii Clinics at Kakaako, Honolulu

Sponsors
All Listed Sponsors
collaborator

Neuraltus Pharmaceuticals, Inc.

INDUSTRY

lead

Beau Nakamoto

OTHER